missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human IKAROS (aa 402-464) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (87%), Rat (87%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-111054 (PA5-111054. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
DNA-binding protein IKAROS functions in the specification and the maturation of the T lymphocyte. It also interacts with a critical control element in the terminal deoxynucleotidyl transferase promoter as well as with the promoters for other genes expressed during early stages of B-cell and T-cell development.
Specifications
Specifications
| Accession Number | Q13422 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 10320 |
| Name | Human IKAROS (aa 402-464) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 5832432G11Rik; CLL-associated antigen KW-6; CVID13; DNA-binding protein Ikaros; hIk-1; hlk-1; Hs0.5445; IK1; IKAROS; IKAROS family zinc finger 1; IKAROS family zinc finger 1 (Ikaros); ikaros family zinc finger protein 1; IKZF1; KAROS family zinc finger 1 (Ikaros); LYF1; LyF-1; Lymphoid transcription factor LyF-1; mKIAA4227; PPP1R92; PRO0758; protein phosphatase 1, regulatory subunit 92; RGD1562979; Zfpn1a1; zinc finger containing transcription factor; zinc finger protein, subfamily 1 A, 1 (Ikaros); Znfn1a1 |
| Common Name | IKAROS |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction